Impact of medical care including anti-infective agents use on the prognosis of COVID-19 hospitalized patients over time
Davido et al.,
Impact of medical care including anti-infective agents use on the prognosis of COVID-19 hospitalized patients..,
Int. J. Antimicrobial Agents, 2020, doi:10.1016/j.ijantimicag.2020.106129
Retrospective of 132 hospitalized patients. HCQ+AZ(52)/AZ(28) significantly reduced death/ICU, HR=0.45, p=0.04. Adjusted for Charlson Comorbidity Index (including age), obesity, O2, lymphocyte count, and treatments. Mean delay from admission to treatment 0.7 days.
risk of intubation/hospitalization, 55.0% lower, HR 0.45, p = 0.04, treatment 12 of 80 (15.0%), control 13 of 40 (32.5%), NNT 5.7.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Davido et al., 2 Aug 2020, retrospective, France, peer-reviewed, 14 authors.
Abstract: Version of Record: https://www.sciencedirect.com/science/article/pii/S0924857920303125
Manuscript_8414355259043bebf7cba1d22abeb157
1
Impact of medical care including anti-infective agents use on the prognosis of
2
COVID-19 hospitalized patients over time
3
Benjamin Davido1, Ghilas Boussaid2, Isabelle Vaugier3, Thibaud Lansaman4,
4
Frédérique Bouchand5, Christine Lawrence6, Jean-Claude Alvarez7, Pierre Moine8,
5
Véronique Perronne1, Frédéric Barbot3, Azzam Saleh-Mghir1, Christian Perronne1,
6
Djillali Annane8, Pierre De Truchis1, on behalf of the COVID-19 RPC Team*
7
1
8
Garches, France
9
2
Université Paris-Saclay, UVSQ, Erphan, 78000, Versailles, France.
10
3
Centre d’Investigation Clinique (Inserm CIC 1429), Université Paris-Saclay, AP-HP
11
Hôpital Raymond Poincaré, Garches, France
12
4
13
Poincaré, Garches, France
14
5
15
Poincaré, Garches, France
16
6
EOH, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches, France
17
7
Pharmaco-toxicologie, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré,
18
Garches, France
19
8
20
Garches, France
Maladies Infectieuses, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré,
Rééducation fonctionnelle, Université Paris-Saclay, AP-HP Hôpital Raymond
Pharmacie Hospitalière, Université Paris-Saclay, AP-HP Hôpital Raymond
Réanimation médicale, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré,
21
22
Keywords: azithromycin, hydroxychloroquine, Covid-19, pneumonia
1
© 2020 published by Elsevier. This manuscript is made available under the Elsevier user license
https://www.elsevier.com/open-access/userlicense/1.0/
23
24
25
26
27
Corresponding author:
28
Benjamin Davido, Service de Maladies Infectieuses et Tropicales
29
Hôpital Raymond-Poincaré, Garches 92380, France.
30
Tel: +33-1-47107758, e-mail: benjamin.davido@aphp.fr
31
32
33
34
35
36
37
38
39
40
Abstract:
41
Introduction: Interest of anti-infective agents in COVD-19 showed discrepant results.
42
However, there is no evaluation about the impact in changes of practices on the
43
prognosis over time.
44
Methods: Single center, retrospective study, conducted from March 5th to April 25th
45
2020, in adults hospitalized in a medicine ward for a COVID-19. Patient
46
characteristics were compared between 2 periods (before/after March 19th)
47
considering French guidelines issued by learned societies. Aim of the study was to
2
48
evaluate how medical care impacted unfavorable outcome, namely admission in
49
intensive care unit (ICU) and/or death.
50
Results: One hundred thirty-two patients were admitted, mean age was 59.0 ± 16.3
51
years,
52
count<1000/mm3. When prescribed, anti-infective agents were lopinavir-ritonavir
53
(n=12), azithromycin (AZI) (n=28) and AZI combined with hydroxychloroquine (HCQ)
54
(n=52). Between the 2 periods we noted a significant decrease of ICU admission,
55
from 43% to 12% (p<0.0001). Delays until transfer in ICU were similar between
56
periods (p=0.86). Pulmonary CT-scan were significantly more performed (from 50%
57
to 90%, p<0.0001), as oxygen-dependency (53% vs 80%, p=0.001) and prescription
58
of AZI±HCQ (from 25% to 76%, p<0.0001) were greater over time. Multivariate
59
analyses showed a reduction of unfavorable outcome in patients receiving AZI±HCQ
60
(HR=0.45, 95%IC [0.21-0.97], p=0.04), especially among an identified category of
61
individuals (lymphocyte≥1000/mm3 or CRP≥100..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit